Day: July 28, 2023

WMSL 759 Builder’s Trials Calhoun (WMSL 759) pictured in the Gulf of Mexico during builder’s trials in June 2023. Calhoun is the 10th NSC to be constructed at HII’s Ingalls Shipbuilding division.PASCAGOULA, Miss., July 28, 2023 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division announced today the successful completion of acceptance sea trials for the U.S. Coast Guard‘s newest national security cutter, Calhoun (WMSL 759). During the trial, the ship spent time proving the ship’s systems including performing numerous tests in the areas of propulsion, electric plant, and mission systems. “Our joint Ingalls and Coast Guard team has completed another successful sea trial, and I am pleased to say NSC 10 performed well,” Ingalls Shipbuilding President Kari Wilkinson said. “Our shipbuilders are now one step closer...

CALGARY, Alberta, July 28, 2023 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, August 11, 2023, at 8:00 a.m. MST / 10:00 a.m. EST. The conference call may be accessed by dial in or via webcast:Pre-register for the Conference Call: https://dpregister.com/sreg/10181515/fa1851b734Dial In Toll Free: 1-844-784-1724Participant International Dial In: 1-412-317-6716Canada Toll Free: 1-866-450-4696Colombia Toll Free 01800-9-156803UK Toll Free: 08082389064Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=P55pKZvb   All...

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of ordinary shares sold in this offering to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity...

New York/Malmö, July 28, 2023 (GLOBE NEWSWIRE) — byNordic Acquisition Corporation (NASDAQ: BYNO) (the “Company”) today announced several actions being undertaken in anticipation of the previously announced special meeting of stockholders of the Company to be held at 10:00 a.m. Eastern Time on August 8, 2023 (the “Special Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend (the “Extension”) the date (the “Original Termination Date”) by which the Company must consummate an initial business combination  from August 11, 2023 to February 12, 2024  (the “Initial Extended Date”) or such earlier date as determined by the Company’s board of directors (the “Board”), in its sole discretion, and to allow the Company by resolution of the Board without another stockholder vote, to elect to extend...

BURR RIDGE, Ill., July 28, 2023 (GLOBE NEWSWIRE) — BankFinancial Corporation (Nasdaq – BFIN) (the “BankFinancial”) filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and a Quarterly Financial and Statistical Supplement in Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) today. BankFinancial reported net income for the three months ended June 30, 2023, of $2.3 million, or $0.18 per common share, compared to net income of $2.6 million, or $0.19 per common share, for the three months ended June 30, 2022. At June 30, 2023, BankFinancial had total assets of $1.527 billion, total loans of $1.171 billion, total deposits of $1.304 billion and stockholders’ equity of $152 million. The Quarterly Report on Form 10-Q and the Quarterly Financial and Statistical Supplement will be available...

Vancouver, BC, July 28, 2023 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the “Company”) today announced the resignation of Steve Marshall, Chief Executive Officer, due to health reasons. The Board has reviewed comprehensive medical history dating back to November 2022, demonstrating continuous inquiries into a pulmonary pathology associated with suspected chronic obstructive pulmonary disease alleviated by doctor-prescribed Symbicort. Despite mandated vaccinations and correctly administered boosters, Mr. Marshall suffered three particularly aggressive bouts of COVID-19 between January 2020 and July 2022. Due to the recent worsening of symptoms, physicians have not ruled out Long COVID. Under a consensus medical recommendation, the latest medical reports show that Mr....

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying OKYO that, for the previous 30 consecutive business days, the market value of OKYO’s ordinary shares had closed below the minimum $35 million requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”). The Nasdaq deficiency letter has no immediate effect on...